Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging ...
The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Stocktwits on MSN
Genmab reports mixed results from late-stage trial of lymphoma drug
Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in ...
Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in ...
A man with a common form of leukaemia has become the first patient to receive a pioneering new treatment on the NHS after it ...
The Dr. Sajad Zalzala Scholarship for Healthcare Professionals announces a $1,500 scholarship opportunity designed to support undergraduate students committed to transforming healthcare through ...
Novartis has announced that ianalumab has received Breakthrough Therapy designation from the US FDA to treat Sjögren’s disease.
US FDA grants Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease: Basel Monday, January 19, 2026, 12:00 Hrs [IST] Novartis announced that the US Fo ...
The Daily Monitor on MSN
The interaction between tuberculosis (TB), HIV and cancer
TB remains the leading cause of death among people living with HIV. Uganda is a high TB-burden country, and HIV accelerates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback